Idiopathic Aplastic anemia: Indian Perspective

Area of Science:

• Hematology
• Immunology
• Oncology

Background:

• Aplastic anemia (AA) is a rare, immune-mediated bone marrow failure causing pancytopenia.
• Distinguishing AA from inherited bone marrow failure syndromes (IMBFS) is crucial due to differing prognoses and treatments.
• Hematopoietic stem cell transplant (HSCT) with a matched sibling donor (MSD-HSCT) remains the only curative option.

Purpose of the Study:

• To review the challenges in managing aplastic anemia in India.
• To evaluate current and emerging treatment strategies for aplastic anemia.
• To highlight the need for novel therapeutic agents.

Main Methods:

• Review of current literature on aplastic anemia management.
• Analysis of treatment challenges specific to the Indian healthcare context.
• Discussion of existing therapies like immunosuppressive therapy (IST) and HSCT.

Main Results:

• MSD-HSCT is curative but limited by donor availability and cost.
• Intensified IST (e.g., ATG, CsA, eltrombopag) shows promise but faces resource limitations.
• Cyclosporine-A (CsA) with androgens is common in India due to cost and HSCT/ATG limitations.
• Relapse, myelodysplasia, and paroxysmal nocturnal hemoglobinuria (PNH) are complications of IST.
• Unrelated donor HSCT data in India is limited.

Conclusions:

• Aplastic anemia management in India is complex, requiring tailored approaches.
• Current treatments have limitations regarding efficacy, cost, and availability.
• There is a critical need for novel agents with improved efficacy and safety profiles for aplastic anemia.